"Innovation-focused investors face a persistent dilemma: how to capture exposure to disruptive technologies without overpaying for hype or concentrating too heavily in mega-cap names. iShares Exponential Technologies ETF ( NASDAQ:XT) attempts to solve this by spreading capital across 500+ holdings targeting AI, genomics, robotics, and other exponential-growth sectors. After a decade in the market, the fund's track record reveals whether this diversified innovation bet delivers on its promise."
"XT positions itself as a core technology and healthcare growth sleeve for investors who want broader innovation exposure than traditional tech indexes provide. The fund allocates 30.2% to information technology and 16% to healthcare, with meaningful positions in semiconductors, cybersecurity, biotech, and cloud infrastructure. Top holdings include Eli Lilly ( NYSE:LLY) (2.82%), Tesla ( NASDAQ:TSLA | TSLA Price Prediction) (2.78%), and NVIDIA ( NASDAQ:NVDA) (2.23%), but no single position exceeds 3%, creating a more balanced profile than concentrated tech funds."
iShares Exponential Technologies ETF (XT) spreads capital across more than 500 companies targeting AI, genomics, robotics, semiconductors, cybersecurity, biotech, and cloud infrastructure with the goal of capital appreciation. The portfolio allocates about 30.2% to information technology and 16% to healthcare, and caps individual holdings below roughly 3%, producing a more balanced profile than concentrated tech funds. Annual turnover runs near 43% to rebalance toward emerging leaders. Assets under management are about $3.7 billion and the expense ratio is 0.46%. Short-term returns have outpaced major benchmarks while five-year results are more mixed.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]